Parkinson’s disease (PD), a prevalent neurodegenerative brain disease, is marked by the loss of dopaminergic neurons in the substantia nigra. Recent research has illuminated the significant role of Vitamin D (VD) in the brain, particularly its neuroprotective effects on these neurons. Highlights: Vitamin D’s Role in the Brain: Beyond its well-known functions in bone health, …
Allopregnanolone agonists represent a promising new class of medications for treating depressive disorders. Evidence suggests that allopregnanolone agonists exhibit rapid-onset of antidepressant action – particularly in women with postpartum depression (PPD). Key facts: Allopregnanolone is a neurosteroid that acts as a positive allosteric modulator of GABAA receptors and is decreased in depressive disorders. The allopregnanolone …
Celecoxib, a selective COX-2 inhibitor, shows promise as an effective and safe adjunct treatment for major depression and mania, according to a new comprehensive systematic review. The analysis also found celecoxib improved symptoms when used as a standalone antidepressant in patients with somatic disorders. However, evidence for efficacy in bipolar depression remains unclear. Key Facts: …
The phenomenon of binaural beats and their proposed ability to synchronize brainwave frequencies through a process called brainwave entrainment (BWE) has intrigued neuroscientists and the public for decades. However, the empirical evidence for BWE remains inconclusive. A recent systematic review evaluated 14 studies on binaural beats and EEG markers of brainwave entrainment, finding mixed results …
Pantoprazole and Omeprazole are medications classified as proton-pump inhibitors (PPIs) and are commonly prescribed for the management of medical conditions in which stomach acid reduction is of therapeutic benefit. Chemists at Byk Gulden, a subsidiary of Altana (a German chemical company), are credited with the synthesis of pantoprazole in 1985 – whereas Swedish chemists at …
Lexapro (escitalopram) and Prozac (fluoxetine) are two medications within the selective-serotonin reuptake inhibitors (SSRI) classification that are commonly administered for the treatment of neuropsychiatric disorders. The development of Lexapro (escitalopram) was initiated in 1997 by Lundbeck and Forest Laboratories – whereas the development of Prozac (fluoxetine) was initiated in the 1970s by chemists (Bryan Molloy …
Lyrica (pregabalin) and Neurontin (gabapentin) are both classified as “gabapentinoids” (i.e. α2δ ligands). As gabapentinoids, Lyrica (pregabalin) and Neurontin (gabapentin) are chemical analogues of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid) that interact with α2δ subunit-containing voltage-dependent calcium channels. Development of gabapentin (Neurontin) was initiated in the 1970s by chemists at the pharmaceutical company Parke-Davis – …